
|Articles|September 12, 2017
Tufts Finds Cardiovascular Drug Approval Rate in the US Fell
Advertisement
Tufts Center for the Study of Drug Development recently completed a study, which was released September 12. The findings show that even though the rate at which investigational drugs received marketing approval in the U.S. has declined in recent years, the cardiovascular approval rate trailed other drug approvals, while the time needed to develop cardiovascular drugs rose.
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research
2
Breaking the Efficacy Ceiling in IBD and Beyond
3
ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program
4
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
5



